LAS VEGAS, April 7, 2016 /PRNewswire/ -- DigiPath Inc. (OTCBB and OTCQB: DIGP), an independent cannabis testing and media firm, today announced that its DigiPath Labs subsidiary has been selected by Orange Photonics, Inc. to evaluate its LightLab Marijuana Potency Analyzer. The LightLab Analyzer is a portable photonics based instrument that provides an instant analysis of THC-A, delta-9 THC, CBD-A and CBD potency levels present in cannabis samples.
"There is an emerging market for rapid potency analytics outside of certified cannabis testing labs," says DigiPath Labs Chief Science Officer, Cindy Orser, "these instruments are designed to be rugged, portable and accurate for the four cannabinoids: THCA, delta-9 THC, CBDA and CBD."
DigiPath Labs will systematically collect comparative cannabinoid data from 100 cannabis flower samples using both the LightLab Analyzer and its own state-of-the art testing laboratory. This dataset will enable Orange Photonics to validate its calibration software and provide it with needed data for the marketing of its new LightLab device.
"We are excited to be working with DigiPath Labs in Las Vegas to help validate the LightLab Marijuana Potency Analyzer. We chose to work with Digipath because of their mission-driven commitment to consistent, accurate testing options and standards for the industry," says Dylan Wilks, CEO/CTO of Orange Photonics. "Third party validation is essential for us to ensure the LightLab provides the level of performance the industry wants."
About DigiPath, Inc.
DigiPath, Inc., supports the cannabis industry's best practices for reliable testing, education, and training, and brings unbiased cannabis news coverage to the nation. DigiPath's two business units are DigiPath Labs and TNM News Corp.
For more information, go to www.digipath.com.
Information about Forward-Looking Statements
This press release contains "forward-looking statements" that include information relating to future events, and future financial and operating performance. Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management's good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in, or suggested by, the forward-looking statements. Important factors that could cause these differences include, but are not limited to: the Company's need for additional funding, the demand for the Company's products, governmental regulation of the cannabis industry, the introduction of new products, the Company's ability to maintain customer and strategic business relationships, the impact of competitive products and pricing, growth in targeted markets, the adequacy of the Company's liquidity and financial strength to support its growth, and other information that may be detailed from time-to-time in the Company's filings with the United States Securities and Exchange Commission. For a more detailed description of the risk factors and uncertainties affecting DigiPath, please refer to the Company's recent Securities and Exchange Commission filings, which are available at www.sec.gov. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/digipath-labs-selected-to-evaluate-orange-photonics-lightlab-marijuana-potency-analyzer-300247714.html
SOURCE DigiPath, Inc.